ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries
(collectively “Aspen” or “the Company”)

RELEASE OF INTEGRATED REPORT, B-BBEE VERIFICATION CERTIFICATE AND FURTHER NOTICE OF
ANNUAL GENERAL MEETING

1. POSTING OF AGM NOTICE AND ABBREVIATED REPORT

Shareholders are advised that the Company’s Integrated Report for the year ended 30 June 2023 has
been finalised and that the notice of the annual general meeting (“AGM”) to be held at its Durban
offices on 7 December 2023 is in the process of being posted to shareholders, along with a set of
abbreviated annual financial statements (“AFS”). The following documents are now available on the
Company’s        website        www.aspenpharma.com          (at      the      following      link
https://www.aspenpharma.com/investor-information/):

- Integrated Report for the 2023 financial year;
- Notice of AGM and proxy in respect of the AGM to be held on 7 December 2023;
- Reports of the Aspen Audit & Risk and Social & Ethics committees for the 2023 financial year;
- Full AFS for the 2023 financial year (as approved by the Company’s Board on 4 October 2023 and
uploaded to the Company’s website on that date – shareholders are referred to the No Change
Statement and Notice of Annual General Meeting as released on 4 October 2023); and
- Various other reports supplementary to the Integrated Report.

2. NOTICE OF AGM

Further notice is hereby given that the 25th annual general meeting of the shareholders of the
Company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office
Park, Durban, Kwa-Zulu Natal, on Thursday, 7 December 2023 at 10:00. Should you choose to attend
the meeting in person, please contact the Company Secretary at cosec@aspenpharma.com / 031 580
8699 by no later than 10:00 on Tuesday, 5 December 2023 in order for seating arrangements to be
confirmed.

The record date on which a person must be registered as a shareholder in the register of the Company
for purposes of being entitled to attend and participate in, and speak and vote at, the meeting is Friday,
1 December 2023. Accordingly, the last day to trade in order to be registered in the register of
members of the Company and therefore be eligible to participate in and vote at the annual general
meeting is Tuesday, 28 November 2023. Shareholders are requested, but are not obliged, to submit
their completed forms of proxy to the Company’s transfer secretaries (JSE Investor Services) before
10:00 on Tuesday, 5 December 2023.

Shareholders who, for whatever reason, experience postal delays and, as a consequence, do not
receive the notice of the AGM in time to submit proxy forms to the Company’s share transfer
secretaries (JSE Investor Services) are requested to access the notice of AGM and other documents
referred to above on the Company’s website www.aspenpharma.com. A printable version of these
documents in PDF format can also be emailed to shareholders upon request to the Company Secretary
– cosec@aspenpharma.com or +27 31 580 8699.

Electronic participation
Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by
way of telephone / video conference call, and if they wish to do so:

    •   Must contact the Company Secretary (by email at the address cosec@aspenpharma.com) by
        no later than 10:00 on Friday 1 December 2023 in order to obtain the dial-in details /
        meeting link in order to participate in the meeting;
    •   Will be required to provide reasonably satisfactory identification; and
    •   Will be billed separately by their own service providers for the costs incurred in respect of
        their telephone / video call to participate in the meeting.

3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE

Shareholders are hereby notified that in accordance with paragraph 16.21(g) and Appendix 1 to
Section 11 of the JSE Listings Requirements, the Company has completed the B-BBEE verification
process and has obtained a Level 4 B-BBEE rating. The verification certificate in terms of section 13G
(2) of the Broad-Based Black Empowerment Amendment Act 46 of 2013, has been published and is
available on the Company’s website www.aspenpharma.com.

Durban
27 October 2023

Sponsor
Investec Bank Limited